More importantly, plitidepsin lacks clinically relevant toxicity of bone marrow; so, plitidepsin is the ideal candidate to treat multiple myeloma patients with poor bone marrow reserve who were heavily pre-treated (Mateos et al., 2010). Multiple myeloma can be heavily pre-treated with chemotherapy, steroids, biological therapy, intensive treatment or even stem cell transplant (Cancer Research UK, 2015, para. 2). However, if the myeloma returns after these treatments given, doctors would advise various combinations of drugs which will cause the myeloma to be even more difficult to treat (Cancer Research UK, 2015, para. 3). Plitidepsin, like the other types of chemotherapy, has the ability to damage cells as they divide; therefore, plitidepsin can kill these harmful myeloma cells (Cancer Research UK, 2015,
More importantly, plitidepsin lacks clinically relevant toxicity of bone marrow; so, plitidepsin is the ideal candidate to treat multiple myeloma patients with poor bone marrow reserve who were heavily pre-treated (Mateos et al., 2010). Multiple myeloma can be heavily pre-treated with chemotherapy, steroids, biological therapy, intensive treatment or even stem cell transplant (Cancer Research UK, 2015, para. 2). However, if the myeloma returns after these treatments given, doctors would advise various combinations of drugs which will cause the myeloma to be even more difficult to treat (Cancer Research UK, 2015, para. 3). Plitidepsin, like the other types of chemotherapy, has the ability to damage cells as they divide; therefore, plitidepsin can kill these harmful myeloma cells (Cancer Research UK, 2015,